ALLC 1992: all centres/groups, trials/strata and treatments

Key: Green - ineligible for overview, nonstandard randomisation or otherwise excluded; Blue - data not (yet) received

11 AIEOP, Italy {Masera, Valsecchi: APR-1993 (UPDATED FOUR TIMES)}

1101 79A AIEOP 7901/7902, duration of maintenance: Low and Average Risk; Entry FEB-1981 to AUG-1983; 1:1 and 2:1 Randomisation; 146 patients were entered

1 Methotrexate + 6-Mercaptopurine + Vincristine + Prednisone x 2yr
2 Methotrexate + 6-Mercaptopurine + Vincristine + Prednisone x 3yr

1102 79B AIEOP 79: High risk; Entry FEB-1979 to SEP-1986; 186 patients were entered

1 Induction: Vincristine + Prednisone + Cytosine Arabinoside + Methotrexate (id) + (Methotrexate + Cytosine Arabinoside) (it)
1 Consolidation: Cytosine Arabinoside + 6-Thioguanine + L-Asparaginase + Doxorubicin + (Methotrexate + Cytosine Arabinoside) (it)
2 Induction: Vincristine + Prednisone + Daunorubicin + Cyclophosphamide + Methotrexate (id) + Methotrexate (it)
2 Consolidation: Cytosine Arabinoside + 6-Thioguanine + L-Asparaginase + Methotrexate (it) + Cranial Irradiation [18Gy]

1103 80F Patients in second CR: Children; Maintenance; Entry 1980 to 1983; 84 patients were entered (not received)

1 (Teniposide + Cytosine Arabinoside) + (Vincristine + Methotrexate + 6-Mercaptopurine + Prednisone) + (Doxorubicin + L-Asparaginase) + (Vincristine + Cyclophosphamide + Cytosine Arabinoside + Prednisone) + (Cyclophosphamide + Methotrexate + Folinic Acid + Prednisone)
2 ((Vincristine + Methotrexate + 6-Mercaptopurine + Prednisone) + (Daunorubicin + Cytosine Arabinoside + 6-Thioguanine + L-Asparaginase) + (Vincristine + Cyclophosphamide + Cytosine Arabinoside + Prednisone)) then ((Cytosine Arabinoside + Methotrexate) + (Vincristine + Prednisone))

1104 91D1 IDH-ALL-91: Standard Risk; Maintenance; Age 1-15; Entry MAR-1991 ff. (not received)

1 6-Mercaptopurine [daily] + Methotrexate [weekly]
2 6-Mercaptopurine [daily] + Methotrexate [weekly] + L-Asparaginase [25kU/m² weekly] x 20

1105 91D2 AIEOP-9102-HR: High Risk; Maintenance; Entry MAR-1991 ff. (not received)

1 6-Mercaptopurine [daily] + Methotrexate [weekly]
2 6-Mercaptopurine [daily] + Methotrexate [weekly] + L-Asparaginase [25kU/m² weekly] x 20

12 BFM Group, Germany {:}

1201 76A ALL-BFM-76: High risk; Age < 18; Entry 1976 to 1979; 41 patients were entered (not received)

1 Early reinduction therapy
2 Late reinduction therapy

1202 79C1 ALL-BFM-79, standard risk: Age < 18; Entry 1979 to 1981; 199 patients were entered (not received)

1 6-Mercaptopurine + Methotrexate + Vincristine + Prednisone (3 pulses)
2 6-Mercaptopurine + Methotrexate

1203 79C2 ALL-BFM-79, high risk: Age < 18; Entry 1979 to 1981; 126 patients were entered (not received)

1 Early reinduction therapy
2 Late reinduction therapy

1204 81A1 ALL-BFM-81, any risk, duration of maintenance: Age < 18; Entry 1981 to 1983; 400 patients were entered (not received)

1 (Methotrexate + 6-Mercaptopurine) x 18m
2 (Methotrexate + 6-Mercaptopurine) x 24m

1205 81A2 ALL-BFM-81, standard risk: CNS prophylaxis; Age < 18; Entry 1981 to 1983; 277 patients were entered (not received)

1 Cranial Irradiation [18Gy]
2 Methotrexate [0·5g/m²] x 4

1206 83C1 ALL-BFM-83, any risk, duration of maintenance: Age < 18; Entry 1983 to 1986; 346 patients were entered (not received)

1 (Methotrexate + 6-Mercaptopurine) x 18m
2 (Methotrexate + 6-Mercaptopurine) x 24m

1207 83C2 ALL-BFM-83, low risk: Age < 18; Entry 1983 to 1986; 126 patients were entered (not received)

1 Intensive reinduction with (Dexamethasone + Vincristine + Doxorubicin + L-Asparaginase + 6-Thioguanine + Cytosine Arabinoside + Methotrexate (it))
2 Control

1208 83C3 ALL-BFM-83, low risk, CNS prophylaxis: Age < 18; Entry 1983 to 1986; 143 patients were entered (not received)

1 Cranial Irradiation [18Gy]
2 Cranial Irradiation [12Gy]

1209 85D ALL-REZ-BFM-85: Relapsed Disease; Children; Entry 1985 to 1987; 130 patients were entered (not received)

1 Methotrexate [1g/m² in 36h] + Leucovorin
2 Methotrexate [12g/m² in 4h] + Leucovorin [higher dose]

1210 82D ALL-BFM-??: Immunotherapy; Age ?; Entry 1982 ff; ? patients were entered (not received)

1 Cytomegalic Hyperimmune Globulin Preparation
2 Control

13 Bombay, India {Kurkure, Shetty: NOV-1992}

1301 79D Bombay TAT TMC 1: Maintenance; Age 2-14; Entry 1979 to 1980; ? patients were entered (not received)

1 6-Mercaptopurine + Methotrexate
2 6-Mercaptopurine + Methotrexate + Vincristine + Prednisone

14 Cancer and Leukemia Group B, U.S.A. {:}

1401 ALGB: Maintenance; Age < 20; Entry ????; 116 patients were entered (not received)

1 (Methotrexate [12mg/m²] + 6-Mercaptopurine) combined
2 (Methotrexate [12mg/m²] + 6-Mercaptopurine) alternating
3 (Methotrexate [12mg/m²] + 6-Mercaptopurine) combined + Folinic Acid (it)

1402 66A1 ALGB 6601, consolidation: Age < 20; Entry 1966 to 1968; ? patients were entered (not received)

1 Methotrexate [12mg/m²]
2 Methotrexate [15mg/m²]
3 Methotrexate [18mg/m²]

1403 66A2 ALGB 6601, maintenance: Age < 20; Entry 1966 to 1968; 211 patients were entered (not received)

1 No further therapy
2 Methotrexate (twice weekly)
3 Methotrexate (daily) x 8m
4 (Methotrexate (daily) + Vincristine + Prednisone) x 8m

1404 68A1 ALGB 6801, induction: Age < 21; Entry 1968 ff; ? patients were entered (not received)

1 L-Asparaginase + Vincristine + Prednisone
2 L-Asparaginase + Vincristine + Prednisone + Daunorubicin
3 Vincristine + Prednisone
4 Vincristine + Prednisone + Daunorubicin

1405 68A2 ALGB 6801, consolidation: Age < 21; Entry 1968 ff; 225 patients were entered (not received)

1 Methotrexate (it)
2 Control

1406 68A3 ALGB 6801, maintenance: Age < 21; Entry 1968 ff; ? patients were entered (not received)

1 Methotrexate [15mg/m²] 2 x wk + Vincristine + Prednisone
2 Methotrexate [15mg/m²] 2 x wk + Vincristine + Prednisone + Daunorubicin
3 6-Mercaptopurine + Methotrexate [15mg/m²] wkly + Vincristine + Prednisone
4 6-Mercaptopurine + Methotrexate [15mg/m²] wkly + Vincristine + Prednisone + Daunorubicin

1407 71A1 CLB 7111, induction: Children; Entry 1971 to 1974; 646 patients were entered (not received)

1 Vincristine [2mg/m²/wk, iv] + Prednisone [40mg/m²/d, po]
2 (Vincristine [2mg/m²/wk, iv] + Prednisone [40mg/m²/d, po]) + L-Asparaginase [1000U/kg/d, iv] x 10d
3 (Vincristine [2mg/m²/wk, iv] + Prednisone [40mg/m²/d, po]) then L-Asparaginase [1000U/kg/d, iv] x 10d
4 L-Asparaginase [1000U/kg/d, iv] x 10d then (Vincristine [2mg/m²/wk, iv] + Prednisone [40mg/m²/d, po])
5 Vincristine [2mg/m²/wk, iv] + Dexamethasone [6mg/m²/d, po]
6 (Vincristine [2mg/m²/wk, iv] + Dexamethasone [6mg/m²/d, po]) + L-Asparaginase [1000U/kg/d, iv] x 10d
7 (Vincristine [2mg/m²/wk, iv] + Dexamethasone [6mg/m²/d, po]) then L-Asparaginase [1000U/kg/d, iv] x 10d
8 L-Asparaginase [1000U/kg/d, iv] x 10d then (Vincristine [2mg/m²/wk, iv] + Dexamethasone [6mg/m²/d, po])

1408 71A2 CLB 7111, CNS prophylaxis: Children; Entry 1971 to 1974; 493 patients were entered (not received)

1 Methotrexate [12mg/m²/wk, it] x 6 + Cranial Irradiation [24Gy]
2 Methotrexate [12mg/m²/wk, it] x 6

1409 71A3 CLB 7111, maintenance: Children; Entry 1971 to 1974; 425 patients were entered (not received)

1 Methotrexate [15mg/m²/d, im] + 6-Mercaptopurine [600mg/m²/d, iv] + Vincristine [? dose] + Prednisone/Dexamethasone
2 Methotrexate [15mg/m²/wk, po] + 6-Mercaptopurine [90mg/m²/?, po] + Vincristine [2mg/m²/?, iv] + Prednisone/Dexamethasone

1410 71B1 CLB 7112, induction, relapse trial: Children; Entry 1971 to 1971; 88 patients were entered (not received)

1 Vincristine + Cyclophosphamide + Prednisone + L-Asparaginase
2 Vincristine + Cyclophosphamide + Prednisone

1411 71B2 CLB 7112, CNS prophylaxis, relapse trial: Children; Entry 1971 to 1971; 45 patients were entered (not received)

1 Cytosine Arabinoside + Prednisone + Carmustine
2 Cytosine Arabinoside + Prednisone + Cyclophosphamide

1412 72A1 CLB 7211, induction, relapse trial: Children; Entry 1972 to 1972; 139 patients were entered (not received)

1 Vincristine + Prednisone + L-Asparaginase + Cyclophosphamide
2 Vincristine + Prednisone + L-Asparaginase

1413 72A2 CLB 7211, CNS prophylaxis, relapse trial: Children; Entry 1972 to 1972; 91 patients were entered (not received)

1 Cyclophosphamide + Vincristine + Prednisone + Lomustine
2 Cyclophosphamide + Vincristine + Prednisone

1414 74A1 CLB 7411, CNS prophylaxis: Children; Entry 1974 to 1977; 339 patients were entered (not received)

1 Methotrexate (it) + Cranial Irradiation [24Gy]
2 Methotrexate (it)

1415 74A2 CLB 7411, maintenance: Children; Entry 1974 to 1977; ? patients were entered (not received)

1 'Standard' maintenance
2 'Pulse' Methotrexate
3 'Pulse' Methotrexate + 6-Mercaptopurine

1416 76B1 CLB 7611: CNS prophylaxis; Age < 20; Entry 1976 to 1979; 634 patients were entered (not received)

1 Methotrexate (it) + Cranial Irradiation [24Gy]
2 Methotrexate (it) + Methotrexate [0·5g/m²] + Folinic Acid

1417 76B2 CLB 7611R: In CR for more than 3 yr; Children; Entry 1980 to 1981; ? patients were entered (not received)

1 Vincristine + L-Asparaginase + Methotrexate + Prednisone
2 No further treatment

1418 76C CLB 7811: Maintenance; Relapsed; Age < 20; Entry 1978 to 1979; ? patients were entered (not received)

1 Methotrexate [? dose] + Folinic Acid + 6-Thioguanine + Vincristine + Prednisone + Methotrexate (it)
2 Methotrexate + Cyclophosphamide + Cytosine Arabinoside + 6-Thioguanine + Vincristine + Prednisone + Methotrexate (it)

1419 76E1 CLB ????, induction: Age > 20; Entry 1976 to 1978; 108 patients were entered (not received)

1 Vincristine + Prednisone + L-Asparaginase
2 Vincristine + Prednisone + L-Asparaginase + Daunorubicin

1420 76E2 CLB ????, maintenance: Age > 20; Entry 1976 to 1978; 78 patients were entered (not received)

1 MER
2 Control

1421 80G CLB 8011: Consolidation; Age 15-79; Entry 1980 to 1985; 158 patients were entered (not received)

1 (6-Mercaptopurine + Methotrexate) x 2
2 (Daunorubicin + Cytosine Arabinoside) [3+7] then (Daunorubicin + Cytosine Arabinoside) [2+5]

1422 85E CLB 8513: Age > 15; Entry OCT-1985 to MAR-1988; 177 patients were entered (not received)

1 Induction: (Mitozantrone + Vincristine + Prednisone + Methotrexate) + Methotrexate (it) + Leucovorin
1 Consolidation: (Daunorubicin + Vincristine + Prednisone + Methotrexate) + Methotrexate (it) + Leucovorin + (Mitozantrone + Vincristine + Prednisone + Methotrexate) + Methotrexate (it) + Leucovorin + Cytosine Arabinoside + 6-Mercaptopurine + L-Asparaginase (Schedule 1)
2 Induction: (Daunorubicin + Vincristine + Prednisone + Methotrexate) + Methotrexate (it) + Leucovorin
2 Consolidation: (Daunorubicin + Vincristine + Prednisone + Methotrexate) + Methotrexate (it) + Leucovorin + (Mitozantrone + Vincristine + Prednisone + Methotrexate) + Methotrexate (it) + Leucovorin + Cytosine Arabinoside + 6-Mercaptopurine + L-Asparaginase (Schedule 2)

1423 69B1 CLB 6911, 4-Way, Induction: Age < 20; Relapsed or Refractory Disease; Entry MAR-1969 to JAN-1970; ? patients were entered (not received)

1 L-Asparaginase [5000U/kg/wk, iv]
2 L-Asparaginase [1000U/kg/wk, iv]
3 L-Asparaginase [5000U/kg/wk, iv] + Vincristine + Daunorubicin + Prednisone
4 L-Asparaginase [1000U/kg/wk, iv] + Vincristine + Daunorubicin + Prednisone

1424 69B2 CLB 6911, 2-Way, Induction: Age < 20; Relapsed or Refractory Disease; Entry JAN-1970 to SEP-1970; ? patients were entered (not received)

1 L-Asparaginase [5000U/kg/wk, iv] + Vincristine + Daunorubicin + Prednisone
2 L-Asparaginase [1000U/kg/wk, iv] + Vincristine + Daunorubicin + Prednisone

1425 69B3 CLB 6911, Maintenance: Age < 20; Relapsed or Refractory Disease; Entry MAR-1969 to SEP-1970; ? patients were entered (not received)

1 (Methotrexate + Folinic Acid) + (Vincristine + Daunorubicin + Prednisone)
2 (Methotrexate + Folinic Acid) + (Vincristine + Daunorubicin + Prednisone) + L-Asparaginase
3 Control

1426 71F1 CALGB-7113 Induction: Entry 1971 to 1976; Age > 19; 169 patients were entered (not received)

1 Vincristine + L-Asparaginase + Prednisone + Methotrexate (it)
2 Vincristine + L-Asparaginase + Prednisone

1427 71F2 CALGB-7113 Maintenance: Entry 1971 to 1976; Age > 19; 100 patients were entered (not received)

1 ((Methotrexate [15mg/m²/d im x 5d] x 2 then 6-Mercaptopurine [600mg/m²/d iv x 5d] x 2) + Vincristine + Prednisone + Carmustine) until relapse
2 (Methotrexate [15mg/m²/d po] + 6-Mercaptopurine [40mg/m²/d po] + Vincristine + Prednisone) until relapse

15 Cape Town University, South Africa {:}

1501 82A1 CT LEU CYC A, immunotherapy: Age > 14; Entry 1982 ff; ? patients were entered (0 children were entered) (not received)

1 Corynebacterium Parvum
2 Control

1502 82A2 CT LEU CYC A, consolidation and maintenance: Age > 14; Entry 1982 ff; ? patients were entered (0 children were entered) (not received)

1 Vincristine + Doxorubicin + L-Asparaginase + Prednisone
2 Cyclophosphamide + Vincristine + Cytosine Arabinoside + Prednisone

1503 86E CT ALL 2: Maintenance; Age 14-70; Entry 1986 ff; ? patients were entered (0 children were entered) (not received)

1 (Methotrexate + 6-Mercaptopurine) + (Cyclophosphamide + Vincristine + Cytosine Arabinoside + Prednisone)
2 (Methotrexate + 6-Mercaptopurine) + (Vincristine + L-Asparaginase + Doxorubicin)

1504 79S CT LEU 2: Adults; Entry 1979 to 1981; ? patients were entered (0 children were entered) (not received)

1 Corynebacterium Parvum
2 Control

1505 77B Maintenance: Adults; Entry 1977 to 1985; ? patients were entered (0 children were entered) (not received)

1 (Methotrexate + 6-Mercaptopurine) + Vincristine + Doxorubicin + L-Asparaginase
2 (Methotrexate + 6-Mercaptopurine) + COAP

16 Children's Cancer Study Group, U.S.A. {Gaynon, Sather, Trigg: FEB-1993 (REVISED VERSION, UPDATED)}

1601 72B CCG-101: Consolidation; Age < 18; Entry JUL-1972 to AUG-1974; 601 patients were entered; 'ineligibles' missing

1 Craniospinal Radiotherapy [24Gy] + Radiotherapy (extended field)
2 Craniospinal Radiotherapy [24Gy]
3 Cranial Irradiation [24Gy]
4 Methotrexate (it)

1602 75A CCG-M-101: Maintenance; Age < 18; Entry OCT-1975 to AUG-1978; 244 patients were entered; 'ineligibles' missing

1 (6-Mercaptopurine + Methotrexate + Vincristine + Prednisone) x 5yr
2 (6-Mercaptopurine + Methotrexate + Vincristine + Prednisone) x 3yr

1603 83D1 CCG-105, induction, consolidation and maintenance: Intermediate prognosis; Children; Entry 1983 to 1989; 1606 patients were entered (synthetic dates only)

1 Induction: Vincristine + Daunorubicin + Prednisone + L-Asparaginase + Methotrexate (it)
1 Consolidation: 6-Mercaptopurine + Cyclophosphamide + Cytosine Arabinoside + Methotrexate (it)
1 Maintenance: (6-Mercaptopurine + Methotrexate) + (Daunorubicin + Methotrexate + Vincristine + Doxorubicin + L-Asparaginase) + (Cyclophosphamide + 6-Thioguanine + Cytosine Arabinoside) + Methotrexate (it) + (Vincristine + Prednisone + 6-Mercaptopurine + Methotrexate) + (Nil/Methotrexate (it))
2 Induction: Vincristine + Prednisone + L-Asparaginase + Methotrexate (it)
2 Consolidation: Vincristine + 6-Mercaptopurine + Methotrexate (it)
2 Maintenance: (6-Mercaptopurine + Methotrexate) + (Daunorubicin + Methotrexate + Vincristine + Doxorubicin + L-Asparaginase) + (Cyclophosphamide + 6-Thioguanine + Cytosine Arabinoside) + Methotrexate (it) + (Vincristine + Prednisone + 6-Mercaptopurine + Methotrexate) + (Nil/Methotrexate (it))
3 Induction: Vincristine + Daunorubicin + Prednisone + L-Asparaginase + Methotrexate (it)
3 Consolidation: 6-Mercaptopurine + Cyclophosphamide + Cytosine Arabinoside + Methotrexate (it)
3 Maintenance: Vincristine + Prednisone + 6-Mercaptopurine + Methotrexate + (Nil/Methotrexate (it))
4 Induction: Vincristine + Prednisone + L-Asparaginase + Methotrexate (it)
4 Consolidation: Vincristine + 6-Mercaptopurine + Methotrexate (it)
4 Maintenance: Vincristine + Prednisone + 6-Mercaptopurine + Methotrexate + (Nil/Methotrexate (it))

1604 83D2 CCG-105, CNS prophylaxis: Intermediate prognosis; Children; Entry 1983 to 1987; 1324 patients were entered (synthetic dates only)

1 Cranial Irradiation [18Gy] + Methotrexate (it) continuing
2 Methotrexate (it) continuing

1605 83E1 CCG-106 - 3 arm: Poor prognosis without lymphomatous features; Age 1-20; Entry 1983 to 1984; 217 patients were entered (synthetic dates only)

1 Induction: Prednisone + Vincristine + Daunorubicin + L-Asparaginase + (Methotrexate + Cytosine Arabinoside) (it)
1 Consolidation: Cyclophosphamide + 6-Mercaptopurine + Cytosine Arabinoside + Methotrexate (it) + Cranial Irradiation
1 Maintenance: (6-Mercaptopurine + Methotrexate) + (Daunorubicin + Methotrexate + Vincristine + Doxorubicin + L-Asparaginase) + (Cyclophosphamide + 6-Thioguanine + Cytosine Arabinoside) + Methotrexate (it) + (Vincristine + Prednisone + 6-Mercaptopurine + Methotrexate) + Methotrexate (it)
2 Induction: Cyclophosphamide + Prednisone + Vincristine + Daunorubicin + L-Asparaginase + (Methotrexate + Cytosine Arabinoside) (it) + Radiotherapy
2 Consolidation: Vincristine + Cytosine Arabinoside + 6-Thioguanine + L-Asparaginase + Methotrexate + Methotrexate (it) + Cranial Irradiation
2 Maintenance: (6-Thioguanine + Cyclophosphamide) + (Vincristine + Prednisone) + (Vincristine + Methotrexate) + (Doxorubicin + Cytosine Arabinoside + 6-Thioguanine) + Methotrexate (it)
3 Induction: Prednisone + Vincristine + L-Asparaginase + Methotrexate (it)
3 Consolidation: 6-Mercaptopurine + Methotrexate (it) + Cranial Irradiation
3 Maintenance: Prednisone + Vincristine + 6-Mercaptopurine + Methotrexate

1606 83E2 CCG-106 - 2 arm: Poor prognosis without lymphomatous features; Age 1-20; Entry 1984 to 1987; 328 patients were entered (synthetic dates only)

1 Induction: Prednisone + Vincristine + Daunorubicin + L-Asparaginase + (Methotrexate + Cytosine Arabinoside) (it)
1 Consolidation: Cyclophosphamide + 6-Mercaptopurine + Cytosine Arabinoside + Methotrexate (it) + Cranial Irradiation
1 Maintenance: (6-Mercaptopurine + Methotrexate) + (Daunorubicin + Methotrexate + Vincristine + Doxorubicin + L-Asparaginase) + (Cyclophosphamide + 6-Thioguanine + Cytosine Arabinoside) + Methotrexate (it) + (Vincristine + Prednisone + 6-Mercaptopurine + Methotrexate) + Methotrexate (it)
2 Induction: Cyclophosphamide + Prednisone + Vincristine + Daunorubicin + L-Asparaginase + (Methotrexate + Cytosine Arabinoside) (it) + Radiotherapy
2 Consolidation: Vincristine + Cytosine Arabinoside + 6-Thioguanine + L-Asparaginase + Methotrexate + Methotrexate (it) + Cranial Irradiation
2 Maintenance: (6-Thioguanine + Cyclophosphamide) + (Vincristine + Prednisone) + (Vincristine + Methotrexate) + (Doxorubicin + Cytosine Arabinoside + 6-Thioguanine) + Methotrexate (it)

1607 83A CCG-121: Maintenance; Marrow relapse; Children; Entry 1982 to 1986; 119 patients were entered (not received)

1 Cytosine Arabinoside + Teniposide + Vincristine + Methotrexate + L-Asparaginase
2 Vincristine + Methotrexate + L-Asparaginase

1608 83B1 CCG-123 - first stratum, 3-way: Poor prognosis with lymphomatous features, without CNS disease; Age 1-20; Entry 1983 to 1985; 272 patients were entered (synthetic dates only)

1 Induction: Vincristine + Daunorubicin + L-Asparaginase + Prednisone + (Methotrexate + Cytosine Arabinoside) (it)
1 Consolidation: Cyclophosphamide + 6-Mercaptopurine + Cytosine Arabinoside + Methotrexate (it) + Cranial Irradiation [18Gy]
1 Maintenance: (6-Mercaptopurine + Methotrexate) + (Daunorubicin + Methotrexate + Vincristine + Doxorubicin + L-Asparaginase) + (Cyclophosphamide + 6-Thioguanine + Cytosine Arabinoside) + Methotrexate (it) + (Vincristine + Prednisone + 6-Mercaptopurine + Methotrexate) + Methotrexate (it)
2 Induction: Cyclophosphamide + Vincristine + Daunorubicin + Prednisone + (Methotrexate + Cytosine Arabinoside) (it) + Radiotherapy (nonabdominal bulk disease)
2 Consolidation: Cytosine Arabinoside + 6-Thioguanine + L-Asparaginase + Carmustine + Methotrexate (it) + Radiotherapy (cranial)
2 Maintenance: 6-Thioguanine + Hydroxyurea + Cyclophosphamide + Daunorubicin + Methotrexate + Carmustine + Cytosine Arabinoside + Vincristine + Methotrexate (it)
3 Induction: Cyclophosphamide + Vincristine + Daunorubicin + Prednisone + (Methotrexate + Cytosine Arabinoside) (it) + Radiotherapy (nonabdominal bulk disease)
3 Consolidation: Cytosine Arabinoside + 6-Thioguanine + L-Asparaginase + Carmustine + Methotrexate (it)
3 Maintenance: 6-Thioguanine + Hydroxyurea + Cyclophosphamide + Daunorubicin + Methotrexate + Carmustine + Cytosine Arabinoside + Vincristine + Methotrexate (it)

1609 83B2 CCG-123 - second stratum: Poor prognosis with lymphomatous features; Age 1-20; Entry NOV-1985 to 1987; 14 patients were entered (synthetic dates only)

1 Induction: Vincristine + Daunorubicin + L-Asparaginase + Prednisone + (Methotrexate + Cytosine Arabinoside) (it)
1 Consolidation: Cyclophosphamide + 6-Mercaptopurine + Cytosine Arabinoside + Methotrexate (it) + Radiotherapy (cranial)
1 Maintenance: (6-Mercaptopurine + Methotrexate) + (Daunorubicin + Methotrexate + Vincristine + Doxorubicin + L-Asparaginase) + (Cyclophosphamide + 6-Thioguanine + Cytosine Arabinoside) + Methotrexate (it) + (Vincristine + Prednisone + 6-Mercaptopurine + Methotrexate) + Methotrexate (it)
2 Induction: Cyclophosphamide + Vincristine + Daunorubicin + Prednisone + (Methotrexate + Cytosine Arabinoside) (it) + Radiotherapy (nonabdominal bulk disease)
2 Consolidation: Cytosine Arabinoside + 6-Thioguanine + L-Asparaginase + Carmustine + Methotrexate (it) + Radiotherapy (cranial)
2 Maintenance: 6-Thioguanine + Hydroxyurea + Cyclophosphamide + Daunorubicin + Methotrexate + Carmustine + Cytosine Arabinoside + Vincristine + Methotrexate (it)

1610 83B3 CCG-123 - third stratum: Poor prognosis with lymphomatous features; Age 1-20; Entry DEC-1985 to 1989; 183 patients were entered (synthetic dates only)

1 Induction: Vincristine + Daunorubicin + L-Asparaginase + Prednisone + (Methotrexate + Cytosine Arabinoside) (it)
1 Consolidation: Cyclophosphamide + 6-Mercaptopurine + Cytosine Arabinoside + Methotrexate (it) + Radiotherapy (cranial)
1 Maintenance: (6-Mercaptopurine + Methotrexate) + (Daunorubicin + Methotrexate + Vincristine + Doxorubicin + L-Asparaginase) + (Cyclophosphamide + 6-Thioguanine + Cytosine Arabinoside) + Methotrexate (it) + (Vincristine + Prednisone + 6-Mercaptopurine + Methotrexate) + Methotrexate (it)
2 Induction: Cyclophosphamide + Vincristine + Daunorubicin + Prednisone + (Methotrexate + Cytosine Arabinoside) (it) + Radiotherapy (nonabdominal bulk disease)
2 Consolidation: Cytosine Arabinoside + 6-Thioguanine + L-Asparaginase + Carmustine + Methotrexate (it) + Radiotherapy (cranial)
2 Maintenance: 6-Thioguanine + Hydroxyurea + Cyclophosphamide + Daunorubicin + Methotrexate + Carmustine + Cytosine Arabinoside + Vincristine + Methotrexate (it)
3 Induction: Cyclophosphamide + Prednisone + Vincristine + Daunorubicin + L-Asparaginase + (Methotrexate + Cytosine Arabinoside) (it) + Radiotherapy
3 Consolidation: Prednisone + Vincristine + Cytosine Arabinoside + 6-Thioguanine + L-Asparaginase + Methotrexate + Methotrexate (it) + Radiotherapy
3 Maintenance: 6-Thioguanine + Cyclophosphamide + Vincristine + Prednisone + Methotrexate + Doxorubicin + Cytosine Arabinoside + Methotrexate (it)

1611 84A CCG-139: Intermediate prognosis; Age 1-20; Entry 1984 to 1988; 123 patients were entered (synthetic dates only)

1 6-Mercaptopurine + Methotrexate (it) + Methotrexate [500mg/m² in 24h, iv] x 3 + Vincristine + Prednisone + 6-Mercaptopurine + Methotrexate (it) + Methotrexate (po) + Methotrexate [500mg/m² in 24h, iv] x 19
2 6-Mercaptopurine + Methotrexate (it) + (Vincristine + Prednisone + 6-Mercaptopurine + Methotrexate (it) + Methotrexate (po)) different schedule

1612 75B1 CCG-141, induction and consolidation: Age < 21; Entry FEB-1975 to MAR-1977; 316 patients were entered; 'ineligibles' missing

1 (Prednisone + Vincristine + L-Asparaginase) + (Prednisone + Vincristine + Methotrexate + 6-Mercaptopurine)
2 (Prednisone + Vincristine + L-Asparaginase + Cyclophosphamide) + (Prednisone + Vincristine + Methotrexate + 6-Mercaptopurine + Cytosine Arabinoside + Doxorubicin)

1613 75B2 CCG-141A, Maintenance I: Poor prognosis; Age < 21; Entry MAY-1977 to JUL-1978; 300 patients were entered

1 6-Mercaptopurine + Methotrexate + Vincristine + Prednisone
2 6-Mercaptopurine + Methotrexate + Vincristine + Prednisone then 2 reinduction courses with Vincristine + Prednisone + L-Asparaginase at 6m and 12m

1614 75B3 CCG-141A, Maintenance II: Poor prognosis; Age < 21; Entry MAR-1978 to JUL-1979; 301 patients were entered

1 6-Mercaptopurine + Methotrexate + (Vincristine + Prednisone) pulses
2 6-Mercaptopurine + Methotrexate

1615 75B4 CCG-M-141, duration of maintenance: Age < 21; Entry MAR-1978 to JUN-1980; 312 patients were entered; 'ineligibles' missing

1 (6-Mercaptopurine + Methotrexate) x 3yr
2 (6-Mercaptopurine + Methotrexate) x 3yr then (Prednisone + Vincristine + L-Asparaginase) x 4wk (reinduction)
3 (6-Mercaptopurine + Methotrexate) x 5yr

1616 74B1 CCG-143: CNS prophylaxis; Age < 18; Entry AUG-1974 to APR-1975; 181 patients were entered; 'ineligibles' missing

1 Craniospinal Irradiation [18Gy]
2 Cranial Irradiation [18Gy]

1617 74B2 CCG-M-143, duration of maintenance: Age < 18; Entry SEP-1977 to AUG-1978; 72 patients were entered; 'ineligibles' missing

1 (6-Mercaptopurine + Methotrexate + Vincristine + Prednisone) x 5yr
2 (6-Mercaptopurine + Methotrexate + Vincristine + Prednisone) x 3yr

1618 78A1 CCG-161, irradiation: Good prognosis; Age 3-6; WBC < 10; Entry 1978 to OCT-1982; 529 patients were entered (synthetic dates only)

1 Cranial Irradiation [18Gy] + Methotrexate (it)
2 Methotrexate (it)

1619 78A2 CCG-161, chemotherapy: Good prognosis; Age 3-6; WBC < 10; Entry 1978 to MAY-1983; 625 patients were entered (synthetic dates only)

1 6-Mercaptopurine + Methotrexate
2 6-Mercaptopurine + Methotrexate + Vincristine + Prednisone

1621 78A3 CCG-M-161, duration of maintenance: Good prognosis; Age 3-6; WBC < 10; Entry 1980 to 1985; 285 patients were entered (synthetic dates only)

1 (Methotrexate + 6-Mercaptopurine + Methotrexate (it) + (Vincristine + Prednisolone)/Nil) x 2yr
2 (Methotrexate + 6-Mercaptopurine + Methotrexate (it) + (Vincristine + Prednisolone)/Nil) x 3yr

1622 78B1 CCG-162, maintenance: Intermediate prognosis; Age < 20; Entry 1978 to 1981; 1058 patients were entered (synthetic dates only)

1 6-Mercaptopurine + Methotrexate (po) + Vincristine + Prednisone
2 6-Mercaptopurine + Methotrexate (it) + Vincristine + Prednisone
3 6-Mercaptopurine + Methotrexate (po) + Vincristine + Prednisone + Cytosine Arabinoside + Cyclophosphamide + Doxorubicin
4 6-Mercaptopurine + Methotrexate (it) + Vincristine + Prednisone + Cytosine Arabinoside + Cyclophosphamide + Doxorubicin
5 6-Mercaptopurine + Methotrexate (po) + Vincristine + Prednisone + L-Asparaginase [6000U/m², im] x 18
6 6-Mercaptopurine + Methotrexate (it) + Vincristine + Prednisone + L-Asparaginase [6000U/m², im] x 18

1623 78B2 CCG-162A: Maintenance; Intermediate prognosis; Age < 20; 1:2:2 randomisation; Entry 1981 to 1983; 541 patients were entered (synthetic dates only)

1 6-Mercaptopurine + Methotrexate + Vincristine + Prednisone
2 (6-Mercaptopurine + Methotrexate + Vincristine + Prednisone + Cyclophosphamide) sequential
3 (6-Mercaptopurine + Methotrexate + Vincristine + Prednisone + Cyclophosphamide) concurrent

1624 78B3 CCG-M-162, duration of maintenance: Intermediate prognosis; Age < 20; Entry 1980 to 1985; 716 patients were entered (synthetic dates only)

1 (Methotrexate + 6-Mercaptopurine (po/it) + Vincristine + Prednisone + Asparaginase/(Cytosine Arabinoside + Cyclophosphamide + Doxorubicin)/Cyclophosphamide/Nil) x 2yr
2 (Methotrexate + 6-Mercaptopurine (po/it) + Vincristine + Prednisone + Asparaginase/(Cytosine Arabinoside + Cyclophosphamide + Doxorubicin)/Cyclophosphamide/Nil) x 3yr

1625 78C1 CCG-163, maintenance: Poor prognosis; Age < 21; WBC > 50; Entry 1978 to 1981; 321 patients were entered (synthetic dates only)

1 6-Mercaptopurine + Methotrexate + Methotrexate (it) + Vincristine + Cytosine Arabinoside + Cyclophosphamide + Doxorubicin + Prednisone
2 6-Mercaptopurine + Vincristine + Methotrexate + Methotrexate (it) + Prednisone + (Cyclophosphamide + Vincristine + Prednisone) + (Vincristine + Prednisone + Doxorubicin + Cytosine Arabinoside) + Methotrexate [1g/m² in 42h]

1626 78C2 CCG-M-163, duration of maintenance: Poor prognosis; Age < 21; WBC > 50; Entry 1981 to 1985; 120 patients were entered (synthetic dates only)

1 (Methotrexate + 6-Mercaptopurine + Vincristine + Prednisone + Methotrexate (it) + Cytosine Arabinoside + Cyclophosphamide + Doxorubicin + (Methotrexate [1g/m², iv])/Nil) x 2yr
2 (Methotrexate + 6-Mercaptopurine + Vincristine + Prednisone + Methotrexate (it) + Cytosine Arabinoside + Cyclophosphamide + Doxorubicin + (Methotrexate [1g/m², iv])/Nil) x 3yr

1627 79E CCG-171: Maintenance; Marrow relapse; Children; Entry 1979 to 1982; 97 patients were entered (not received)

1 Methotrexate + L-Asparaginase
2 Methotrexate + L-Asparaginase + Vincristine
3 (Methotrexate + L-Asparaginase + Vincristine) different schedule

1628 89A CCG-1881: Maintenance; Age 2-9; Entry 1989 ff; ? patients were entered (not received)

1 6-Mercaptopurine + Methotrexate + Vincristine + Prednisone + Methotrexate (it)
2 (Daunorubicin + Methotrexate + Vincristine + Doxorubicin + L-Asparaginase) + (Cyclophosphamide + 6-Thioguanine + Cytosine Arabinoside) + Methotrexate (it) + (6-Mercaptopurine + Methotrexate + Vincristine + Prednisone + Methotrexate (it))

1629 CCG-1882: Entry ????; ? patients were entered (not received)

1 (unknown)
2 (unknown)

1630 CCG-1884: Entry ????; ? patients were entered (not received)

1 (unknown)
2 (unknown)

1631 CCG-1891: Entry ????; ? patients were entered (not received)

1 (unknown)
2 (unknown)

1632 CCG-1901: Entry ????; ? patients were entered (not received)

1 (unknown)
2 (unknown)

1633 __A1 Relapsed Patients: Entry ????; Children; 164 patients were entered (not received)

1 L-Asparaginase [1400U/kg/wk iv]
2 L-Asparaginase [1400U/kg/wk im]

1634 __A2 Relapsed Patients in New CR: Entry ????; Children; 50 patients were entered (not received)

1 L-Asparaginase [1400U/kg/wk im]
2 Control

1635 83B4 CCG-123 - fourth stratum: Poor prognosis with lymphomatous features; Age 1-20; Entry MAY-1987 to 1989; 209 patients were entered (synthetic dates only)

1 Induction: Vincristine + Daunorubicin + L-Asparaginase + Prednisone + (Methotrexate + Cytosine Arabinoside) (it)
1 Consolidation: Cyclophosphamide + 6-Mercaptopurine + Cytosine Arabinoside + Methotrexate (it) + Radiotherapy (cranial)
1 Maintenance: (6-Mercaptopurine + Methotrexate) + (Daunorubicin + Methotrexate + Vincristine + Doxorubicin + L-Asparaginase) + (Cyclophosphamide + 6-Thioguanine + Cytosine Arabinoside) + Methotrexate (it) + (Vincristine + Prednisone + 6-Mercaptopurine + Methotrexate) + Methotrexate (it)
2 Induction: Cyclophosphamide + Prednisone + Vincristine + Daunorubicin + L-Asparaginase + (Methotrexate + Cytosine Arabinoside) (it) + Radiotherapy
2 Consolidation: Prednisone + Vincristine + Cytosine Arabinoside + 6-Thioguanine + L-Asparaginase + Methotrexate + Methotrexate (it) + Radiotherapy
2 Maintenance: 6-Thioguanine + Cyclophosphamide + Vincristine + Prednisone + Methotrexate + Doxorubicin + Cytosine Arabinoside + Methotrexate (it)

1636 83B5 CCG-123 - first stratum, 2-way: Poor prognosis with lymphomatous features and CNS disease; Age 1-20; Entry 1983 to 1985; 272 patients were entered (synthetic dates only)

1 Induction: Vincristine + Daunorubicin + L-Asparaginase + Prednisone + (Methotrexate + Cytosine Arabinoside) (it)
1 Consolidation: Cyclophosphamide + 6-Mercaptopurine + Cytosine Arabinoside + Methotrexate (it) + Cranial Irradiation [18Gy]
1 Maintenance: (6-Mercaptopurine + Methotrexate) + (Daunorubicin + Methotrexate + Vincristine + Doxorubicin + L-Asparaginase) + (Cyclophosphamide + 6-Thioguanine + Cytosine Arabinoside) + Methotrexate (it) + (Vincristine + Prednisone + 6-Mercaptopurine + Methotrexate) + Methotrexate (it)
2 Induction: Cyclophosphamide + Vincristine + Daunorubicin + Prednisone + (Methotrexate + Cytosine Arabinoside) (it) + Radiotherapy (nonabdominal bulk disease)
2 Consolidation: Cytosine Arabinoside + 6-Thioguanine + L-Asparaginase + Carmustine + Methotrexate (it) + Radiotherapy (cranial)
2 Maintenance: 6-Thioguanine + Hydroxyurea + Cyclophosphamide + Daunorubicin + Methotrexate + Carmustine + Cytosine Arabinoside + Vincristine + Methotrexate (it)

17 Dana Farber Cancer Institute, U.S.A. {Gelber, Sallan: MAR-1992}

1701 73A DFCI 73001: Induction; Entry OCT-1973 to OCT-1974; 45 patients were entered (11 patients missing)

1 Vincristine + Prednisone
2 Vincristine + Prednisone + Doxorubicin
3 Vincristine + Prednisone + Daunorubicin

1702 77A DFCI 77001: Consolidation; Age < 20; Entry JUN-1977 to AUG-1979; 64 patients were entered

1 Vincristine + Prednisone + Doxorubicin
2 Vincristine + Prednisone + Doxorubicin + L-Asparaginase [25000U/m², im] x 24

1703 80A DFCI 80001: Intensification; Entry JAN-1980 to SEP-1980; 22 patients were entered

1 Prednisone + Vincristine + Methotrexate + 6-Mercaptopurine
2 Cyclophosphamide + Vincristine + Prednisone + Doxorubicin

1704 81B DFCI 81001: Pre-induction; Children; Entry MAY-1981 to DEC-1983; 77 patients were entered

1 Methotrexate
2 Methotrexate [4g/m² in 1h (9 patients were given 33g/m²)]

1705 85A DFCI 85001: Pre-induction; Age < 18; Entry APR-1985 to OCT-1987; 210 patients were entered

1 L-Asparaginase (standard dose)
2 L-Asparaginase (high dose)

1706 87E1 DFCI 87001, pre-induction: Age < 18; Entry 1987 to 1991; ? patients were entered (not received)

1 L-Asparaginase (E. Coli)
2 L-Asparaginase (Erwinia)
3 L-Asparaginase (PEG)

1707 87E2 DFCI 87001, induction: Entry 1987 to 1991; ? patients were entered (not received)

1 Methotrexate [40mg/m² iv push] + Vincristine + Prednisone + Doxorubicin
2 Methotrexate [4g/m² iv in 1h] + Vincristine + Prednisone + Doxorubicin

1708 87E3 DFCI 87001, CNS prophylaxis: WBC > 20 or age < 2 or age > 9; Entry 1987 to 1991; ? patients were entered (not received)

1 Craniospinal Irradiation [18Gy as single daily fractions of 1·8Gy]
2 Craniospinal Irradiation [18Gy as twice daily fractions of 0·9Gy]

1709 72F SFCI ???: CNS Prophylaxis; Entry 1972 ff; 20 patients were entered (not received)

1 Methotrexate (it) continuing
2 Methotrexate (it) + Cranial Irradiation [24Gy]

1711 91C DFCI 91-001: Previously untreated; Age < 18; Entry 1991 ff; 40 patients were entered by JAN-1992 (not received)

1 Dexamethasone + L-Asparaginase + 6-Mercaptopurine + Doxorubicin
2 Control
3 Dexamethasone + L-Asparaginase + 6-Mercaptopurine + Doxorubicin + Radiotherapy
4 Radiotherapy

18 Dutch Childhood Leukaemia Study Group, The Netherlands {van der Does - van den Berg, Hermans, Kamps: OCT-1992 (UPDATED)}

1801 79F DCLSG-ALL-V / EORTC 99801: induction; Children; Entry MAY-1979 to NOV-1982; 240 patients were entered

1 Vincristine + Prednisone + L-Asparaginase
2 Vincristine + Prednisone + L-Asparaginase + Rubidomycin

1802 88B SNWLK-ALL-VII: Maintenance; High Risk; Age < 16; Entry 1988 to 1991; ? patients were entered (not received)

1 Methotrexate + 6-Mercaptopurine
2 (Prednisone + Vindesine + Teniposide + Ifosfamide + Cytosine Arabinoside [high dose]) then (Methotrexate + 6-Mercaptopurine)

1803 91E1 SNWLK-ALL-8: Maintenance; Low Risk; Age < 19; Entry 1991 ff; ? patients were entered (not received)

1 Methotrexate + 6-Mercaptopurine
2 Methotrexate + 6-Mercaptopurine + L-Asparaginase [25000U/m²/wk]

1804 91E2 SNWLK-ALL-8: Consolidation; Medium Risk; Age < 19; Entry 1991 ff; ? patients were entered (not received)

1 Methotrexate [5000mg/m², iv] + 6-Mercaptopurine [25mg/m²/d, po] x 56d
2 Methotrexate [5000mg/m², iv] + 6-Mercaptopurine [1300mg/m²/2wk, iv] x 4

1805 91E3 SNWLK-ALL-8: Consolidation; High Risk; Age < 19; Entry 1991 ff; ? patients were entered (not received)

1 Dexamethasone + 6-Mercaptopurine + Vincristine + Methotrexate + Cytosine Arabinoside + L-Asparaginase + Ifosfamide + Etoposide
2 Dexamethasone + 6-Mercaptopurine + Vincristine + Methotrexate + Cytosine Arabinoside + L-Asparaginase + Ifosfamide + Etoposide + G-Colony Stimulating Factor

19 European Organisation for Research on Treatment of Cancer {Otten, Philippe, Stryckmaus, Suciu: NOV-1992 (SECOND REVISED VERSION)}

1901 71C1 EORTC 58741, Consolidation: Age < 50; Entry JUN-1971 to JAN-1979; 224 patients were entered

1 L-Asparaginase + 6-Mercaptopurine + Prednisone + Carmustine + Cyclophosphamide + Methotrexate + Vincristine
2 Methotrexate + Vincristine + Prednisolone

1902 71C2 EORTC 58741, Maintenance: Age < 50; Entry OCT-1972 to APR-1980; 123 patients were entered

1 BCG + Allogeneic leukaemic blast cells
2 (6-Mercaptopurine + Methotrexate + Vincristine + Prednisolone) x 4yr

1903 80B1 EORTC 58791, Induction: Age 1-60; Entry 1980 to 1985; 108 patients were entered (2 children) (not received)

1 Doxorubicin + Vincristine + Prednisone
2 Doxorubicin + Vincristine + Prednisone + Cytosine Arabinoside

1904 80B2 EORTC 58791, Consolidation: Age 1-60; Entry 1980 to 1985; ? patients were entered (not received)

1 (Methotrexate + 6-Thioguanine + Cytosine Arabinoside) + (L-Asparaginase + Cyclophosphamide)
2 L-Asparaginase + Cyclophosphamide

1905 83F EORTC 58831: Consolidation; Standard Risk; Age < 18; Entry AUG-1983 to AUG-1989; 388 patients were entered

1 6-Mercaptopurine + Cytosine Arabinoside + Methotrexate (it) + Cyclophosphamide
2 6-Mercaptopurine + Cytosine Arabinoside + Methotrexate (it)

1906 83G EORTC 58832: Medium and High Risk: Age < 18; Entry SEP-1983 to JUN-1989; 191 patients were entered

1 Methotrexate [2·5g/m²] + Cranial Irradiation [16-24Gy, age-adjusted]
2 Methotrexate [2·5g/m²]

1907 89B1 EORTC 58881, Increased Risk: Age < 18; Entry 1989 ff; 150 patients were entered (by MAR-1991) (not received)

1 6-Mercaptopurine + Methotrexate [5g/m²] + Folinic Acid + Methotrexate (it)
2 6-Mercaptopurine + Methotrexate [5g/m²] + Folinic Acid + Methotrexate (it) + Cytosine Arabinoside [high dose]

1908 89B2 EORTC 58881, Maintenance: Age < 18; Entry 1989 ff; 40 patients were entered (by MAR-1991) (not received)

1 (6-Mercaptopurine + Methotrexate) (po)
2 (6-Mercaptopurine + Methotrexate) (iv and po)

1909 83J EORTC 3811: Antibiotic; Age 14-60; Entry 1983 to 1987; ? patients were entered (not received)

1 Polymyxin B/E + Amphotericin + Nystatin + Neomycin
2 Polymyxin B/E + Amphotericin + Nystatin + Co-trimoxazole

1910 86F EORTC 06861: Post-CR Therapy; Age > 15; Entry 1986 ff; ? patients were entered (not received)

1 Cyclophosphamide + Total Body Irradiation + Autologous Bone Marrow Transplant
2 (Prednisone + Vincristine + Doxorubicin + Carmustine + Cyclophosphamide + 6-Mercaptopurine + Methotrexate + Actinomycin-D) + (6-Mercaptopurine + Methotrexate + Vincristine + Prednisone)

1911 EORTC ????: Age 18-65; Entry ????; 91 patients were entered (not received)

1 Ciprofloxacin [500mg bid]
2 Co-trimoxazole [960mg tid] + Colistin [200mg tid]

1912 EORTC ????: Age ?; Entry ????; ? patients were entered (not received)

1 Ciprofloxacin [1g]
2 Ciprofloxacin [500mg]
3 Norfloxacin [800mg]
4 Norfloxacin [400mg]

20 French A.L.L. Coöperative Group {Bancillon, Richards, Schaison: SEP-1992}

2001 83H1 FRALLE 83, low risk, duration of maintenance: Age 2-10; Entry JUL-1985 to NOV-1988; 66 patients were entered

1 (6-Mercaptopurine + Methotrexate + Vincristine/Vindesine + Prednisone) x 2yr
2 (6-Mercaptopurine + Methotrexate + Vincristine/Vindesine + Prednisone) x 3yr

2002 83H2 FRALLE 83, intermediate risk: Age 2-10; Entry 1983 to 1987; 250 patients were entered (not received)

1 Methotrexate [0·5g/m² in 4h] + (6-Mercaptopurine + Methotrexate) + (Vincristine + Prednisone)
2 Methotrexate [0·5g/m² in 4h] + (Cytosine Arabinoside + L-Asparaginase + Vincristine + Cyclophosphamide + Teniposide + Daunorubicin)
3 (Amsacrine + Cytosine Arabinoside) + (6-Mercaptopurine + Methotrexate) + (Vincristine + Prednisone)
4 (Amsacrine + Cytosine Arabinoside) + (Cytosine Arabinoside + L-Asparaginase + Vincristine + Cyclophosphamide + Teniposide + Daunorubicin)

2003 83H3 FRALLE 83, high risk: Age 2-10; Entry MAY-1983 to SEP-1986; 63 patients were entered

1 Testicular Irradiation [18Gy in 9 fractions]
2 Control

2004 87F FRALLE 87: CNS prophylaxis; Age ?; Entry 1987 ff; ?? patients were entered (not received)

1 Methotrexate [3g/m²]
2 Methotrexate [8g/m²]

2005 83H4 FRALLE 83, low risk, induction: Age 2-10; Entry 1983 to 1987; ? patients were entered (not received)

1 Vincristine + Prednisone
2 Vindesine + Prednisone

2006 83H5 FRALLE 83, intermediate and high risk, induction: Age 2-10; Entry 1983 to 1987; ? patients were entered (not received)

1 Vincristine + Prednisone + Daunorubicin + Cyclophosphamide + L-Asparaginase
2 Vindesine + Prednisone + Daunorubicin + Cyclophosphamide + L-Asparaginase

21 G.A.T.L.A., Argentina {Muriel, Pavlovsky, Santarelli: OCT-1992 (UPDATED TWICE)}

2101 72C1 GATLA 72, consolidation: All ages; Entry AUG-1972 to APR-1976; 390 patients were entered

1 Cytosine Arabinoside + Cyclophosphamide
2 Control

2102 72C2 GATLA 72, maintenance: All ages; Entry AUG-1972 to APR-1976; 390 patients were entered (randomisation date is first of three)

1 (6-Mercaptopurine [600mg/m² po] + Methotrexate [30mg/m²]) weekly + Vincristine + P
2 6-Mercaptopurine [2·5mg/kg po, daily] + Methotrexate [15mg/m²] (2 x wk) + Vincristine + P
3 (6-Mercaptopurine [600mg/m² po] + Methotrexate [30mg/m²]) weekly + Vincristine + P + Methotrexate (it) + Dexamethasone
4 6-Mercaptopurine [2·5mg/kg po, daily] + Methotrexate [15mg/m²] (2 x wk) + Vincristine + P + Methotrexate (it) + Dexamethasone

2103 72C3 GATLA 72, immunotherapy: All ages; Entry 1972 to 1975; ? patients were entered (not received; 'impossible')

1 Levamisole
2 Control

2104 79G GATLA 1 LLA 79: Age < 16; Entry 1979 to 1984; 533 patients were entered (not received)

1 Levamisole daily
2 Levamisole on 2 consecutive days each week

2105 87A GATLA 7-LLA-87: Maintenance; Age < 16; Entry 1987 to 1989; 272 patients were entered (not received)

1 6-Mercaptopurine + Methotrexate [20mg/m²] + Vincristine + Prednisone (standard)
2 (Etoposide + Cyclophosphamide) + (6-Mercaptopurine + Methotrexate [40mg/m²]) + (Teniposide + Cytosine Arabinoside) + (Vincristine + Prednisone) (cyclic)

2106 70D1 GATLA-70a: Children; Entry JUL-1970 to OCT-1972; 126 patients were entered (not received)

1 Induction: Daunorubicin + Vincristine + Prednisone
1 Intensification: L-Asparaginase
1 Maintenance: (6-Mercaptopurine + Methotrexate) + (Daunorubicin + Vincristine + Prednisone)
2 Induction: Daunorubicin + Vincristine + Prednisone
2 Intensification: Control
2 Maintenance: (6-Mercaptopurine + Methotrexate) + (Daunorubicin + Vincristine + Prednisone)
3 Induction: Doxorubicin + Vincristine + Prednisone
3 Intensification: Control
3 Maintenance: (6-Mercaptopurine + Methotrexate) + (Adriamycin + Vincristine + Prednisone)

2107 70D2 GATLA-70b: CNS Prophylaxis; Entry 1970 to 1971; ? patients were entered (not received)

1 Cranial Irradiation + Methotrexate [it] x 5
2 Control

22 Great Ormond Street Hospital, London, U.K. {Chessells: MAY-1992}

2201 79H GOS79: Maintenance; Children; Entry JUN-1979 to DEC-1982; 144 patients were entered

1 Methotrexate [20mg/m² po] + 6-Mercaptopurine + Vincristine + Prednisone
2 Methotrexate [20mg/m² im] + 6-Mercaptopurine + Vincristine + Prednisone

23 Gunma University, Japan {:}

2301 79J Japan KLSG 1: Maintenance; Any age; Entry 1979 to 1982; 15 patients were entered (not received)

1 Cytosine Arabinoside + 6-Mercaptopurine
2 Cytosine Arabinoside + 6-Mercaptopurine + Levamisole

24 Hamburg Universitäts Kinderklinik, Germany {Harms, Janka-Schaub: OCT-1992 (REVISED VERSION (UPDATED))}

2401 78K1 COALL 80: Low Risk; Maintenance; Children; Entry NOV-1978 to NOV-1982; 105 patients were entered

1 6-Mercaptopurine + Methotrexate + Vincristine + Prednisolone
2 6-Mercaptopurine + Methotrexate + Methotrexate [0·5g/m² in 24h] x 6 + Prednisolone

2402 78K2 COALL 80: High Risk; Maintenance; Children; Entry JAN-1979 to AUG-1982; 33 patients were entered

1 6-Mercaptopurine + Methotrexate + Vincristine + Prednisolone
2 6-Mercaptopurine + Methotrexate + Methotrexate [0·5g/m² in 24h] x 6 + Prednisolone

2403 85B1 COALL 85/89: High Risk with HIDAC; Consolidation; Children; Entry JAN-1985 to DEC-1987; 59 patients were entered

1 Slow rotation
2 Rapid rotation

2404 85B2 COALL 85/89: High Risk without HIDAC; Consolidation; Children; Entry JAN-1985 to MAR-1990; 143 patients were entered

1 Slow rotation
2 Rapid rotation

2405 82C COALL 82: Maintenance; Children; Entry 1982 to 1983; ?? patients were entered (not received)

1 6-Mercaptopurine + Methotrexate + Vincristine + Prednisolone
2 6-Mercaptopurine + Methotrexate + Methotrexate [0·5g/m² in 4h] x 6 + Prednisolone

2406 92A1 COALL-91, therapeutic window: Entry 1992 ff; ?? patients were entered (not received)

1 Daunorubicin [1h infusion]
2 Daunorubicin [24h infusion]

2407 92A2 COALL-91, maintenance: Entry 1992 ff; ?? patients were entered (not received)

1 6-Mercaptopurine + Methotrexate
2 6-Thioguanine + Methotrexate

25 Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru {Perez, Solidoro: OCT-1992 (UPDATED TWICE)}

2502 79L INEN-7902: Maintenance; High Risk; Entry JUN-1979 to AUG-1983; 48 patients were entered

1 Cyclophosphamide [2g/m² over 120h, q 8wk x 4 then q 12wk] x 2yr + (6-Mercaptopurine [90mg/m²/d] + Methotrexate [15mg/m²/wk]) x 3yr
2 (Cyclophosphamide [2g/m² over 120h, q 8wk x 4 then q 12wk] + Prednisone [100mg/m²/d, q 8wk x 4 then q 12wk] x 14d) x 2yr + (6-Mercaptopurine [90mg/m²/d] + Methotrexate [15mg/m²/wk]) x 3yr
3 (Cyclophosphamide [2g/m² over 120h, q 8wk x 4 then q 12wk] + (Prednisone [100mg/m²/d, q 8wk x 4 then q 12wk] + Vincristine [1·5mg/m²/d]) x 14d) x 2yr + (6-Mercaptopurine [90mg/m²/d] + Methotrexate [15mg/m²/wk]) x 3yr

2503 83K INEN-P83: Low to Medium Risk; Entry FEB-1983 to AUG-1985; 59 patients were entered

1 Methotrexate [6-12mg twice/wk, it] x 5 then Methotrexate [6-12mg/12wk, it] x 3yr
2 Cranial Irradiation [18Gy, Co⁶⁰] + Methotrexate [6-12mg twice/wk, it] x 5

2504 85C INEN-P85: CNS Prophylaxis (induction was based on drug availability); Low to Medium Risk; Entry JUL-1985 to JUL-1988; 73 patients were entered {imbalance in under-3s is due to chance}

1 (Methotrexate + Cytosine Arabinoside + Hydrocortisone) [twice/wk, it]
2 Cranial Irradiation [18Gy, Co⁶⁰] + Methotrexate [twice/wk, it] x 5

2505 88D INEN-P88: Entry JUN-1988 to DEC-1990; 136 patients were entered (nonstandard randomisation)

1 'Lima Protocol'
2 'Non-Lima Protocol'

2506 91G INEN-P91: Entry 1991 ff; ? patients were entered (nonstandard randomisation) (not received)

1 (blank)
2 (blank)
3 (blank)

26 Japanese Children's Cancer and Leukaemia Group, Japan {Fujimoto: OCT-1992 (UPDATED TWICE)}

2601 80J1 Japan CCLSG S-811, standard risk, Maintenance: Age 1-15; Entry NOV-1980 to JAN-1984; 131 patients were entered

1 6-Mercaptopurine [175mg/m²/d for 5d po] + Methotrexate [225mg/m² iv] + Prednisone + Vincristine ('intermittent' regimen)
2 6-Mercaptopurine [50mg/m²/d po] + Methotrexate [20mg/m²/wk po] + Prednisone + Vincristine ('continuous' regimen)

2602 80J2 Japan CCLSG H-811, high risk, maintenance: Age 1-15; Entry FEB-1981 to AUG-1982; 45 patients were entered

1 Cyclophosphamide + Methotrexate [200mg/kg, iv] weekly
2 Cranial Irradiation [18Gy] + (Methotrexate + Hydrocortisone) (it) + (Cyclophosphamide + Methotrexate [60mg/m², iv]) weekly

2603 84B1 Japan CCLSG I-841, intermediate risk, maintenance: Children; Entry FEB-1984 to MAR-1987; 78 patients were entered

1 Vincristine + Prednisone + Methotrexate + 6-Mercaptopurine + L-Asparaginase
2 Doxorubicin + Methotrexate [high dose] + Vincristine + Prednisone + 6-Mercaptopurine

2604 84B2 Japan CCLSG L-841, low risk, maintenance: Children; Entry FEB-1984 to JUN-1987; 66 patients were entered

1 Vincristine + Prednisone
2 Vincristine + Prednisone + L-Asparaginase [2000U/m², iv] x 20

2605 84G Japan CCLSG H-851, high risk, maintenance: Children; Entry NOV-1984 to JUL-1987; 93 patients were entered

1 (Vincristine + Methotrexate [6g/m² iv] + Folinic Acid) + (6-Mercaptopurine + Prednisone)
2 Vincristine + Prednisone + Cyclophosphamide + Methotrexate [60mg/m² iv] + 6-Mercaptopurine + Doxorubicin

2606 87B1 Japan CCLSG L-874, low risk, CNS prophylaxis: Children; Entry APR-1987 to FEB-1991; 87 patients were entered

1 Cranial Irradiation [18Gy] + (Methotrexate + Hydrocortisone) (it)
2 Methotrexate [2g/m² iv, then 225mg/m² iv] + Methotrexate (it) continuing

2607 87B2 Japan CCLSG I-874, intermediate risk, CNS prophylaxis: Children; Entry APR-1987 to SEP-1991; 114 patients were entered

1 Cranial Irradiation [18Gy]
2 Methotrexate [up to 4·5g/m² iv] + Methotrexate (it)

2608 87B3 Japan CCLSG H-874, high risk, intensification: Children; Entry APR-1987 to DEC-1990; 164 patients were entered

1 Methotrexate [up to 3g/m²] + Cyclophosphamide [400mg/m²] + Cytosine Arabinoside [75mg/m² iv] + 6-Mercaptopurine [60mg/m² po] + Prednisone
2 Methotrexate [up to 3g/m²] + Cyclophosphamide [1200mg/m²] + Cytosine Arabinoside [1500mg/m² iv] + Prednisone

27 Medical Research Council, U.K. {Eden, Richards: SEP-1992}

2701 70A1 UKALL I, CNS prophylaxis: Any age; Entry SEP-1970 to DEC-1971; 194 patients were entered

1 Craniospinal Irradiation + Methotrexate (it)
2 Cytosine Arabinoside (1 extra cycle)

2702 70A2 UKALL I, duration of maintenance: Any age; Entry JAN-1972 to OCT-1973; 83 patients were entered

1 (6-Mercaptopurine + Methotrexate + Vincristine + Prednisolone + (Methotrexate (it))/Nil) x 18m
2 (6-Mercaptopurine + Methotrexate + Vincristine + Prednisolone + (Methotrexate (it))/Nil) x 36m

2703 72D1 UKALL II, CNS Prophylaxis: Age 1-50; Entry JAN-1972 to DEC-1972; 39 patients were entered (not received)

1 Radiotherapy [24Gy, craniospinal]
2 Radiotherapy [24Gy, cranial + 10Gy, spinal] + Methotrexate (it)

2704 72D2 UKALL II, type of maintenance: Any age; Entry JAN-1972 to FEB-1973; 224 patients were entered

1 (Methotrexate + 6-Mercaptopurine + Cytosine Arabinoside + Vincristine + Prednisone) then Cyclophosphamide
2 (Methotrexate + 6-Mercaptopurine + Cytosine Arabinoside + Vincristine + Prednisone)

2705 72D3 UKALL II, duration of maintenance: Any age; Entry OCT-1973 to AUG-1975; 207 patients were entered

1 (Methotrexate + 6-Mercaptopurine + Cytosine Arabinoside + Vincristine + Prednisolone + Cyclophosphamide/Nil) x 2yr
2 (Methotrexate + 6-Mercaptopurine + Cytosine Arabinoside + Vincristine + Prednisolone + Cyclophosphamide/Nil) x 3yr

2706 73B1 UKALL III ord: Standard risk; Age 1-13; WBC < 20; Entry SEP-1973 to NOV-1974; 156 patients were entered

1 L-Asparaginase + Methotrexate
2 L-Asparaginase (different schedule) + Methotrexate (as in arm 1)
3 L-Asparaginase (as in arm 1) + Methotrexate/Cytosine Arabinoside
4 L-Asparaginase (as in arm 2) + Methotrexate/Cytosine Arabinoside (as in arm 3)

2707 73B2 UKALL III mod: Standard risk; Age 1-13; WBC < 20; Entry OCT-1974 to DEC-1975; 132 patients were entered

1 6-Mercaptopurine (continuous)
2 6-Mercaptopurine (intermittent, 1wk in every 4wk off)

2708 73B3 UKALL III, duration of maintenance: Standard risk; Age 1-13; WBC < 20; Entry JUN-1975 to DEC-1977; 249 patients were entered

1 (Methotrexate + 6-Mercaptopurine + Vincristine + Prednisolone + Cytosine Arabinoside/Nil + Asparaginase/Nil) x 2yr
2 (Methotrexate + 6-Mercaptopurine + Vincristine + Prednisolone + Cytosine Arabinoside/Nil + Asparaginase/Nil) x 3yr

2709 75C1 UKALL IV, induction: Age < 14 and WBC > 20 or Age > 13; Entry JAN-1975 to JAN-1978; 431 patients were entered

1 Cyclophosphamide + Vincristine + Cytosine Arabinoside + Prednisolone
2 Vincristine + Prednisolone

2710 75C2 UKALL IV, maintenance: Age < 14; WBC > 20; Entry FEB-1975 to DEC-1977; 336 patients were entered

1 Chemotherapy (intermittent)
2 Chemotherapy (continuous)

2711 75D1 UKALL V, CNS prophylaxis: Age 1-14; Entry MAY-1976 to JUN-1979; 369 patients were entered

1 Cranial Irradiation [24Gy as 12 fractions]
2 Cranial Irradiation [21Gy as 7 fractions]

2712 75D2 UKALL V, maintenance: Age 1-13; Entry OCT-1975 to JUN-1979; 540 patients were entered

1 (Prednisone + Vincristine + 6-Mercaptopurine + Methotrexate) intermittent
2 (Prednisone + Vincristine + 6-Mercaptopurine + Methotrexate) continuous
3 (Prednisone + Vincristine + 6-Mercaptopurine + Methotrexate) 'gaps' chemotherapy

2713 75D3 UKALL V, duration of maintenance: Age 1-14; Entry NOV-1977 to MAY-1981; 305 patients were entered

1 (Methotrexate + 6-Mercaptopurine + Vinmcristine + Prednisolone) x 2yr
2 (Methotrexate + 6-Mercaptopurine + Vinmcristine + Prednisolone) x 3yr

2714 77C1 UKALL VI, induction (children): Age < 14; WBC > 20; Entry JUN-1977 to MAR-1980; 219 patients were entered

1 (Vincristine + Prednisolone) + (Cyclophosphamide + Vincristine + Cytosine Arabinoside + Prednisolone) + (L-Asparaginase + Doxorubicin + Vincristine)
2 (Vincristine + Prednisolone) + (6-Mercaptopurine + L-Asparaginase + Cytosine Arabinoside + Methotrexate [3 x 0·5g/m²] + Folinic Acid)

2715 77C2 UKALL VI, induction (adults): Age > 13; Entry JAN-1978 to APR-1980; 164 patients were entered

1 (Vincristine + Prednisolone) + (Cyclophosphamide + Vincristine + Cytosine Arabinoside + Prednisolone) + (L-Asparaginase + Doxorubicin + Vincristine)
2 (Vincristine + Prednisolone) + (6-Mercaptopurine + L-Asparaginase + Cytosine Arabinoside + Methotrexate [3 x 0·5g/m²] + Folinic Acid)

2716 77C3 UKALL VI, consolidation (first protocol; children): Age < 14; WBC > 20; Entry JAN-1978 to NOV-1978; 62 patients were entered

1 Cranial Irradiation [24Gy in 12 fractions]
2 Cranial Irradiation [21Gy in 7 fractions]

2717 77C4 UKALL VI, consolidation (first protocol, adults): Age > 13; Entry JAN-1978 to NOV-1978; 44 patients were entered

1 Cranial Irradiation [24Gy in 12 fractions]
2 Cranial Irradiation [21Gy in 7 fractions]

2718 77C5 UKALL VI, consolidation (second protocol, children): Age < 14; WBC > 20; Entry JAN-1979 to MAR-1980; 25 patients were entered

1 Cranial Irradiation [24Gy in 12 fractions]
2 Cranial Irradiation [18Gy in 9 fractions]

2719 77C6 UKALL VI, consolidation (second protocol, adults): Age > 13; Entry DEC-1978 to MAR-1980; 46 patients were entered

1 Cranial Irradiation [24Gy in 12 fractions]
2 Cranial Irradiation [18Gy in 9 fractions]

2720 77C7 UKALL VI, Testicular Radiotherapy (children): Age < 14; WBC > 20; Entry JAN-1978 to MAR-1980; 55 patients were entered

1 Testicular Irradiation [12Gy in 6 fractions]
2 Control

2721 77C8 UKALL VI, Testicular Radiotherapy (adults): Age > 13; Entry JAN-1978 to SEP-1979; 21 patients were entered

1 Testicular Irradiation [12Gy in 6 fractions]
2 Control

2722 79M1 UKALL VII, induction: Age < 14; WBC < 20; Entry MAR-1979 to MAR-1980; 82 patients were entered

1 (Allopurinol + Prednisolone + Vincristine + 6-Mercaptopurine) + L-Asparaginase [8 doses in 4wk]
2 (Allopurinol + Prednisolone + Vincristine + 6-Mercaptopurine) + L-Asparaginase [4 doses in 8d]

2723 79M2 UKALL VII, CNS prophylaxis (radiotherapy): Age 1-14; WBC < 20; Entry MAR-1979 to MAR-1980; 82 patients were entered

1 Cranial Irradiation [24Gy in 12 fractions]
2 Cranial Irradiation [18Gy in 9 fractions]

2724 79M3 UKALL VII, CNS prophylaxis (Methotrexate (it)): Age 1-14; WBC < 20; Entry MAR-1979 to MAR-1980; 82 patients were entered

1 Methotrexate (it) x 5
2 Methotrexate (it) x 13

2725 79M4 UKALL VII, Testicular Radiotherapy: Age 1-14; WBC < 20; Entry MAR-1979 to MAR-1980; 43 patients were entered

1 Testicular Irradiation [18Gy in 9 fractions]
2 Control

2726 79M5 UKALL VII, maintenance: Age 1-14; WBC < 20; Entry MAR-1979 to MAR-1980; 82 patients were entered

1 6-Mercaptopurine + Prednisolone + Vincristine + Methotrexate (po)
2 6-Mercaptopurine + Prednisolone + Vincristine + Methotrexate (im)

2727 81C1 UKALL VIII, induction: Age < 14; Entry NOV-1981 to DEC-1984; 630 patients were entered

1 Vincristine + Prednisolone + L-Asparaginase + Methotrexate (it)
2 Vincristine + Prednisolone + L-Asparaginase + Methotrexate (it) + Daunorubicin

2728 81C2 UKALL VIII, duration of maintenance: Age < 14; Entry FEB-1983 to JAN-1987; 408 patients were entered

1 (6-Mercaptopurine + Methotrexate + Prednisone + Vincristine) x 2yr
2 (6-Mercaptopurine + Methotrexate + Prednisone + Vincristine) x 3yr

2729 80C UKALL IX, induction: Age > 14; Entry 1980 to 1985; 268 patients were entered (not received)

1 Prednisone + Vincristine + Erwinia Asparaginase + 6-Mercaptopurine + Methotrexate [intermediate dose]
2 Prednisone + Vincristine + Erwinia Asparaginase + 6-Mercaptopurine + Daunorubicin

2730 84C1 UKALL X: Post-induction intensification; Age < 15; WBC < 100; Entry JAN-1985 to SEP-1990; 1173 patients were entered

1 No intensification
2 (Vincristine + Prednisolone + Daunorubicin + 6-Thioguanine + Etoposide + Cytosine Arabinoside + Methotrexate (it)) early intensification
3 (Vincristine + Prednisolone + Daunorubicin + 6-Thioguanine + Etoposide + Cytosine Arabinoside + Methotrexate (it)) late intensification
4 (Vincristine + Prednisolone + Daunorubicin + 6-Thioguanine + Etoposide + Cytosine Arabinoside + Methotrexate (it)) early and late intensification

2731 84C2 UKALL XA: Post-induction intensification; Age > 14; WBC < 100; Entry 1985 to 1990; ? patients were entered (not received)

1 No intensification
2 (Vincristine + Prednisolone + Daunorubicin + 6-Thioguanine + Etoposide + Cytosine Arabinoside + Methotrexate (it)) early intensification
3 (Vincristine + Prednisolone + Daunorubicin + 6-Thioguanine + Etoposide + Cytosine Arabinoside + Methotrexate (it)) late intensification
4 (Vincristine + Prednisolone + Daunorubicin + 6-Thioguanine + Etoposide + Cytosine Arabinoside + Methotrexate (it)) early and late intensification

2732 90A1 UKALL XI, intensification: Age 2-15; Entry 1990 to MAY-1991; ? patients were entered (not received)

1 (Prednisolone + Vincristine + Daunorubicin + 6-Thioguanine + Etoposide + Cytosine Arabinoside + Methotrexate (it)) + (Vincristine + Prednisone) (late intensification only)
2 (Prednisolone + Vincristine + Daunorubicin + 6-Thioguanine + Etoposide + Cytosine Arabinoside + Methotrexate (it)) + (Vincristine + Prednisone) (early and late intensification)

2733 90A2 UKALL XI, CNS prophylaxis I: Age 3-15; WBC > 50; Entry 1990 ff; ? patients were entered (not received)

1 Methotrexate (it) + Cranial Irradiation [24Gy]
2 Methotrexate (it) + Methotrexate [6 or 8g/m², iv] + continuing Methotrexate (it)

2734 90A3 UKALL XI, CNS prophylaxis II: Age 1-15; WBC < 50; Entry 1990 ff; ? patients were entered (not received)

1 Methotrexate (it) + Methotrexate [6 or 8g/m², iv] + continuing Methotrexate (it)
2 Methotrexate (it) + continuing Methotrexate (it)

2735 91F UKALL R1: Children; Entry 1991 ff; 51 patients were entered by APR-1992 (not received)

1 Cyclophosphamide + TBI + Autologous Bone Marrow Transplant
2 Chemotherapy x 18m

28 National Cancer Institute, U.S.A. {:}

2801 NCI: Maintenance; Children; Entry ????; 49 patients were entered (not received)

1 Prednisone + Vincristine + Methotrexate + 6-Mercaptopurine
2 Prednisone + Vincristine + Methotrexate + 6-Mercaptopurine + BCG + Irradiated allogeneic leukaemic cells

2802 71D NCI-72-1: CNS prophylaxis; Entry 1971 to 1974; ? patients were entered (not received)

1 Cranial Irradiation + Cytosine Arabinoside (it)
2 Cranial Irradiation + Methotrexate (it)

2803 80E NCI-77-02 / CCG-191: High and average risk; Age < 21; Randomisation 1:2; Entry 1980 to 1983; 181 patients were entered (not received)

1 Methotrexate (it) + Cranial Irradiation [24Gy]